

Dhananjay Arun Chitale

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4512471/publications.pdf>

Version: 2024-02-01

92
papers

7,631
citations

136740

32
h-index

54797

84
g-index

95
all docs

95
docs citations

95
times ranked

10739
citing authors

#	ARTICLE	IF	CITATIONS
1	Tribbles 2 pseudokinase confers enzalutamide resistance in prostate cancer by promoting lineage plasticity. <i>Journal of Biological Chemistry</i> , 2022, 298, 101556.	1.6	4
2	Race Differences in Telomere Length in Benign Prostate Biopsies and Subsequent Risk of Prostate Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 991-998.	1.1	8
3	Clinical significance of quantitative categorization of HER2 fluorescent in situ hybridization results in invasive breast cancer patients treated with HER2-targeted agents. <i>Modern Pathology</i> , 2021, 34, 720-734.	2.9	4
4	Multiethnic PDX models predict a possible immune signature associated with TNBC of African ancestry. <i>Breast Cancer Research and Treatment</i> , 2021, 186, 391-401.	1.1	7
5	A serum-based DNA methylation assay provides accurate detection of glioma. <i>Neuro-Oncology</i> , 2021, 23, 1494-1508.	0.6	53
6	Growth and differentiation factor 15 and NF- κ B expression in benign prostatic biopsies and risk of subsequent prostate cancer detection. <i>Cancer Medicine</i> , 2021, 10, 3013-3025.	1.3	10
7	Investigation of triple-negative breast cancer risk alleles in an International African-enriched cohort. <i>Scientific Reports</i> , 2021, 11, 9247.	1.6	12
8	Racial differences in the systemic inflammatory response to prostate cancer. <i>PLoS ONE</i> , 2021, 16, e0252951.	1.1	4
9	Customizable Natural Language Processing Biomarker Extraction Tool. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 833-841.	1.0	4
10	The Potential and Limitations of Precision Oncology: Lessons Learned from Whole-Exome Sequencing in an Exceptional Response to Everolimus in Advanced Renal Cell Carcinoma. <i>Case Reports in Oncology</i> , 2021, 14, 1194-1200.	0.3	1
11	Molecular markers of risk of subsequent invasive breast cancer in women with ductal carcinoma in situ: protocol for a population-based cohort study. <i>BMJ Open</i> , 2021, 11, e053397.	0.8	1
12	Clonal evaluation of early onset prostate cancer by expression profiling of ERG, SPINK1, <i>ETV1</i> , and <i>ETV4</i> on whole-mount radical prostatectomy tissue. <i>Prostate</i> , 2020, 80, 38-50.	1.2	15
13	A pediatric case of pigmented epithelioid melanocytoma with chromosomal copy number alterations in 15q and 17q and a novel <i>NTRK3</i> - <i>ESCAPER</i> gene fusion. <i>Journal of Cutaneous Pathology</i> , 2020, 47, 70-75.	0.7	9
14	Breast and prostate cancers harbor common somatic copy number alterations that consistently differ by race and are associated with survival. <i>BMC Medical Genomics</i> , 2020, 13, 116.	0.7	17
15	A Novel <i>COL1A1-CAMTA1</i> Rearrangement in Cranial Fasciitis. <i>International Journal of Surgical Pathology</i> , 2020, 28, 678-682.	0.4	3
16	Clonal evaluation of prostate cancer molecular heterogeneity in biopsy samples by dual immunohistochemistry and dual RNA in situ hybridization. <i>Modern Pathology</i> , 2020, 33, 1791-1801.	2.9	6
17	The interplay of growth differentiation factor 15 (GDF15) expression and M2 macrophages during prostate carcinogenesis. <i>Carcinogenesis</i> , 2020, 41, 1074-1082.	1.3	11
18	Gene fusion characterisation of rare aggressive prostate cancer variants—adenosquamous carcinoma, pleomorphic giant cell carcinoma, and sarcomatoid carcinoma: an analysis of 19 cases. <i>Histopathology</i> , 2020, 77, 890-899.	1.6	15

#	ARTICLE	IF	CITATIONS
19	Pseudogene Associated Recurrent Gene Fusion in Prostate Cancer. <i>Neoplasia</i> , 2019, 21, 989-1002.	2.3	15
20	Distribution and Short-term Prognostic Value of the 21-gene recurrence score in African American compared to White American breast cancer patients. <i>Breast Journal</i> , 2019, 25, 667-671.	0.4	4
21	Potential effect of anti-inflammatory drug use on PSA kinetics and subsequent prostate cancer diagnosis: Risk stratification in black and white men with benign prostate biopsy. <i>Prostate</i> , 2019, 79, 1090-1098.	1.2	2
22	Atypical Chemokine Receptor 1 (<i>DARC/ACKR1</i>) in Breast Tumors Is Associated with Survival, Circulating Chemokines, Tumor-Infiltrating Immune Cells, and African Ancestry. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 690-700.	1.1	41
23	HER2 Expression in NF1 Breast Cancer Response. <i>Cancer Prevention Research</i> , 2019, 12, 197-198.	0.7	0
24	Ecchymotic Nodule on the Scalp: Answer. <i>American Journal of Dermatopathology</i> , 2019, 41, 612-613.	0.3	0
25	Hereditary Susceptibility for Triple Negative Breast Cancer Associated With Western Sub-Saharan African Ancestry. <i>Annals of Surgery</i> , 2019, 270, 484-492.	2.1	56
26	Ecchymotic Nodule on the Scalp: Challenge. <i>American Journal of Dermatopathology</i> , 2019, 41, e78-e79.	0.3	0
27	Ancillary Studies: Contribution to Error and Error Prevention. , 2019, , 77-106.		0
28	Utilization of the 21-Gene Recurrence Score in a Diverse Breast Cancer Patient Population: Development of a Clinicopathologic Model to Predict High-Risk Scores and Response to Neoadjuvant Chemotherapy. <i>Annals of Surgical Oncology</i> , 2018, 25, 1921-1927.	0.7	8
29	Pseudosarcomatous myofibroblastic proliferations of the genitourinary tract are genetically different from nodular fasciitis and lack <i>USP6</i> , <i>ROS1</i> and <i>ETV6</i> gene rearrangements. <i>Histopathology</i> , 2018, 73, 321-326.	1.6	14
30	Pleomorphic fibroma of the skin with MDM2 immunoreactivity: A potential diagnostic pitfall. <i>Journal of Cutaneous Pathology</i> , 2018, 45, 59-62.	0.7	8
31	Breast cancer risk and germline genomic profiling of women with neurofibromatosis type 1 who developed breast cancer. <i>Genes Chromosomes and Cancer</i> , 2018, 57, 19-27.	1.5	22
32	Association between cadmium and androgen receptor protein expression differs in prostate tumors of African American and European American men. <i>Journal of Trace Elements in Medicine and Biology</i> , 2018, 48, 233-238.	1.5	13
33	Germline and Somatic <i>NF1</i> Alterations Are Linked to Increased HER2 Expression in Breast Cancer. <i>Cancer Prevention Research</i> , 2018, 11, 655-664.	0.7	4
34	Triple-Negative Breast Cancer, Stem Cells, and African Ancestry. <i>American Journal of Pathology</i> , 2018, 188, 271-279.	1.9	33
35	Implementation of precision medicine clinical care pathways and a systemwide molecular tumor board at Henry Ford Health System (HFHS).. <i>Journal of Clinical Oncology</i> , 2018, 36, e18541-e18541.	0.8	0
36	Biological significance of genome-wide DNA methylation profiles in keloids. <i>Laryngoscope</i> , 2017, 127, 70-78.	1.1	19

#	ARTICLE	IF	CITATIONS
37	Renal Cell Carcinoma With Chromosome 6p Amplification Including the TFEB Gene. American Journal of Surgical Pathology, 2017, 41, 287-298.	2.1	60
38	Larger men have larger prostates: Detection bias in epidemiologic studies of obesity and prostate cancer risk. Prostate, 2017, 77, 949-954.	1.2	12
39	Bioenergetic Adaptations in Chemoresistant Ovarian Cancer Cells. Scientific Reports, 2017, 7, 8760.	1.6	119
40	Renal cell tumors with clear cell histology and intact VHL and chromosome 3p: a histological review of tumors from the Cancer Genome Atlas database. Modern Pathology, 2017, 30, 1603-1612.	2.9	30
41	Investigation into the presence of human papillomavirus in patients with obstructive sleep apnea. Laryngoscope, 2017, 127, 1231-1234.	1.1	3
42	Evaluation and Adaptation of a Laboratory-Based cDNA Library Preparation Protocol for Retrospective Sequencing of Archived MicroRNAs from up to 35-Year-Old Clinical FFPE Specimens. International Journal of Molecular Sciences, 2017, 18, 627.	1.8	15
43	Assessment of the Immune Microenvironment in Estrogen Receptor Positive Invasive Breast Cancers and Its Correlation to Clinicopathologic Parameters. American Journal of Clinical Pathology, 2016, 146, .	0.4	0
44	The biological significance of methylome differences in human papilloma virus associated head and neck cancer. Oncology Letters, 2016, 12, 4949-4956.	0.8	8
45	Comparative Analysis of Breast Cancer Phenotypes in African American, White American, and West Versus East African patients: Correlation Between African Ancestry and Triple-Negative Breast Cancer. Annals of Surgical Oncology, 2016, 23, 3843-3849.	0.7	63
46	Methylation in benign prostate and risk of disease progression in men subsequently diagnosed with prostate cancer. International Journal of Cancer, 2016, 138, 2884-2893.	2.3	12
47	Mutational Landscape of Aggressive Prostate Tumors in African American Men. Cancer Research, 2016, 76, 1860-1868.	0.4	61
48	Anti-androgenic activity of absorption-enhanced 3, 3'-diindolylmethane in prostatectomy patients. American Journal of Translational Research (discontinued), 2016, 8, 166-76.	0.0	6
49	Methylation Markers for Early Detection and Differentiation of Follicular Thyroid Cancer Subtypes. Cancer and Clinical Oncology, 2015, 4, 1-12.	0.2	17
50	Inhibition of 5-Lipoxygenase Selectively Triggers Disruption of c-Myc Signaling in Prostate Cancer Cells. Journal of Biological Chemistry, 2015, 290, 4994-5006.	1.6	50
51	Autoantibodies in breast cancer sera are not epiphenomena and may participate in carcinogenesis. BMC Cancer, 2015, 15, 407.	1.1	34
52	Lung and Mediastinal Tumors. , 2015, , 221-268.		0
53	Anti-centrosome antibodies in breast cancer are the expression of autoimmunity. Immunologic Research, 2014, 60, 339-347.	1.3	11
54	Array-CGH Shows Amplification of 8q Including <i>MYC</i> as the Sole Aberration in a Leiomyosarcoma of the Female Lower Genital Tract. Cytogenetic and Genome Research, 2014, 142, 245-248.	0.6	2

#	ARTICLE	IF	CITATIONS
55	Intraoperative Clinical Assessment and Pressure Measurements of Sentinel Lymph Nodes in Breast Cancer. <i>Annals of Surgical Oncology</i> , 2014, 21, 81-85.	0.7	15
56	Admixture Fine-Mapping in African Americans Implicates XAF1 as a Possible Sarcoidosis Risk Gene. <i>PLoS ONE</i> , 2014, 9, e92646.	1.1	31
57	Methylation of the RARB Gene Increases Prostate Cancer Risk in Black Americans. <i>Journal of Urology</i> , 2013, 190, 317-324.	0.2	36
58	Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors. <i>Journal of Molecular Diagnostics</i> , 2013, 15, 415-453.	1.2	397
59	Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. <i>Archives of Pathology and Laboratory Medicine</i> , 2013, 137, 828-860.	1.2	415
60	Adenomyoepithelioma of the Breast: A Brief Diagnostic Review. <i>Archives of Pathology and Laboratory Medicine</i> , 2013, 137, 725-729.	1.2	51
61	Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. <i>Journal of Thoracic Oncology</i> , 2013, 8, 823-859.	0.5	792
62	Differential expression of aurora-A kinase in T-cell lymphomas. <i>Modern Pathology</i> , 2013, 26, 640-647.	2.9	25
63	Prevalence of Terminal Duct Lobular Units and Frequency of Neoplastic Involvement of the Nipple in Mastectomy. <i>Archives of Pathology and Laboratory Medicine</i> , 2013, 137, 955-960.	1.2	25
64	Immunohistochemical staining with EGFR mutation-specific antibodies: high specificity as a diagnostic marker for lung adenocarcinoma. <i>Modern Pathology</i> , 2013, 26, 1197-1203.	2.9	22
65	Precursor Lesions of Mucinous Carcinoma of the Breast. <i>American Journal of Surgical Pathology</i> , 2013, 37, 1076-1084.	2.1	14
66	The CAP-IASLC-AMP molecular testing guideline for the selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors.. <i>Journal of Clinical Oncology</i> , 2013, 31, 11085-11085.	0.8	1
67	Inflammation and preneoplastic lesions in benign prostate as risk factors for prostate cancer. <i>Modern Pathology</i> , 2012, 25, 1023-1032.	2.9	57
68	Reliability of KRAS mutation testing in metastatic colorectal cancer patients across five laboratories. <i>BMC Research Notes</i> , 2012, 5, 196.	0.6	4
69	Disease-free probability after the first primary ductal carcinoma in situ of the breast: a comparison between African-American and White-American women. <i>Breast Cancer Research and Treatment</i> , 2012, 131, 561-570.	1.1	19
70	Loss of Let-7 Up-Regulates EZH2 in Prostate Cancer Consistent with the Acquisition of Cancer Stem Cell Signatures That Are Attenuated by BR-DIM. <i>PLoS ONE</i> , 2012, 7, e33729.	1.1	189
71	The effects of BR-DIM (BioResponse 3, 3- β -Diindolylmethane) administered pre-prostatectomy on the androgen receptor (AR).. <i>Journal of Clinical Oncology</i> , 2012, 30, 1560-1560.	0.8	0
72	Epigenetic silencing of miR-34a in human prostate cancer cells and tumor tissue specimens can be reversed by BR-DIM treatment. <i>American Journal of Translational Research (discontinued)</i> , 2012, 4, 14-23.	0.0	70

#	ARTICLE	IF	CITATIONS
73	Frequency of EGFR and KRAS Mutations in Lung Adenocarcinomas in African Americans. <i>Journal of Thoracic Oncology</i> , 2011, 6, 28-31.	0.5	126
74	DNA Methylation in Thyroid Tumorigenesis. <i>Cancers</i> , 2011, 3, 1732-1743.	1.7	34
75	Angiolipoma of the Female Breast: Clinicomorphological Correlation of 52 Cases. <i>International Journal of Surgical Pathology</i> , 2011, 19, 35-43.	0.4	27
76	Genomic and Biological Characterization of Exon 4 KRAS Mutations in Human Cancer. <i>Cancer Research</i> , 2010, 70, 5901-5911.	0.4	245
77	Clinical Performance of <i>JAK2</i> V617F Mutation Detection Assays in a Molecular Diagnostics Laboratory. <i>American Journal of Clinical Pathology</i> , 2009, 132, 713-721.	0.4	41
78	Mutational Profile of Advanced Primary and Metastatic Radioactive Iodine-Refractory Thyroid Cancers Reveals Distinct Pathogenetic Roles for <i>BRAF</i> , <i>PIK3CA</i> , and <i>AKT1</i> . <i>Cancer Research</i> , 2009, 69, 4885-4893.	0.4	488
79	An integrated genomic analysis of lung cancer reveals loss of <i>DUSP4</i> in EGFR-mutant tumors. <i>Oncogene</i> , 2009, 28, 2773-2783.	2.6	205
80	The Role of Lymph Node Metastasis in the Systemic Dissemination of Breast Cancer. <i>Annals of Surgical Oncology</i> , 2009, 16, 3396-3405.	0.7	44
81	The Henry Ford Production System: LEAN Process Redesign Improves Service in the Molecular Diagnostic Laboratory. <i>Journal of Molecular Diagnostics</i> , 2009, 11, 390-399.	1.2	22
82	EGFR Mutations in Lung Adenocarcinomas. <i>Journal of Molecular Diagnostics</i> , 2008, 10, 242-248.	1.2	180
83	Genetic Predictors of MEK Dependence in Non-Small Cell Lung Cancer. <i>Cancer Research</i> , 2008, 68, 9375-9383.	0.4	235
84	Novel <i>MEK1</i> Mutation Identified by Mutational Analysis of Epidermal Growth Factor Receptor Signaling Pathway Genes in Lung Adenocarcinoma. <i>Cancer Research</i> , 2008, 68, 5524-5528.	0.4	206
85	Frequency and Distinctive Spectrum of <i>KRAS</i> Mutations in Never Smokers with Lung Adenocarcinoma. <i>Clinical Cancer Research</i> , 2008, 14, 5731-5734.	3.2	505
86	Heterogeneity of Breast Cancer Metastases: Comparison of Therapeutic Target Expression and Promoter Methylation Between Primary Tumors and Their Multifocal Metastases. <i>Clinical Cancer Research</i> , 2008, 14, 1938-1946.	3.2	193
87	Prognostic and Therapeutic Implications of EGFR and KRAS Mutations in Resected Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2008, 3, 111-116.	0.5	248
88	<i>MET</i> amplification occurs with or without <i>T790M</i> mutations in <i>EGFR</i> mutant lung tumors with acquired resistance to gefitinib or erlotinib. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 20932-20937.	3.3	1,557
89	Expression of cancer testis antigens in endometrial carcinomas using a tissue microarray. <i>Modern Pathology</i> , 2005, 18, 119-126.	2.9	28
90	False-negative core needle biopsies of the breast. <i>Cancer</i> , 2003, 97, 1824-1831.	2.0	109

#	ARTICLE	IF	CITATIONS
91	Intraspinal Endodermal Cyst: Ultrastructural Study of Abnormal Cilia. Microscopy and Microanalysis, 2003, 9, 183-189.	0.2	1
92	Benign metastasizing chondroblastoma. Cancer, 1998, 82, 675-678.	2.0	47